LEO Pharma A/S – Product Pipeline Review – 2012 by GlobalMarketsDirect

VIEWS: 162 PAGES: 100

More Info
									       LEO Pharma A/S – Product Pipeline Review – 2012


                                                                                          Reference Code: GMDHC02166CDB
                                                                                                 Publication Date: MAY 2012




LEO Pharma A/S – Product Pipeline Review – 2012                                           GMDHC02166CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
LEO Pharma A/S – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 6
    List of Figures ................................................................................................................................................................................ 7
LEO Pharma A/S Snapshot ................................................................................................................................................................ 8
    LEO Pharma A/S Overview ........................................................................................................................................................... 8
    Key Information ............................................................................................................................................................................. 8
    Key Facts....................................................................................................................................................................................... 8
LEO Pharma A/S – Research and Development Overview ................................................................................................................ 9
    Key Therapeutic Areas .................................................................................................................................................................. 9
LEO Pharma A/S – Pipeline Review ................................................................................................................................................ 12
    Pipeline Products by Stage of Development ............................................................................................................................... 12
    Pipeline Products – Monotherapy ............................................................................................................................................... 13
    Pipeline Products – Combination Treatment Modalities .............................................................................................................. 14
LEO Pharma A/S – Pipeline Products Glance .................................................................................................................................. 15
    LEO Pharma A/S – Late Stage Pipeline ...................................................................................................................................... 15
        Phase III Products/Combination Treatment Modalities ........................................................................................................... 15
    LEO Pharma A/S Clinical Stage Pipeline Products ..................................................................................................................... 16
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 16
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 17
    LEO Pharma A/S – Early Stage Pipeline Products ...................................................................................................................... 18
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 18
LEO Pharma A/S – Drug Profiles ..................................................................................................................................................... 19
    LEO 22811 .................................................................................................................................................................................. 19
        Product Description................................................................................................................................................................. 19
        Mechanism of Action ............................................................................................................................................................... 19
        R&D Progress ......................................................................................................................................................................... 19
    LEO 27847 .................................................................................................................................................................................. 20
        Product Description................................................................................................................................................................. 20
        Mechanism of Action ............................................................................................................................................................... 20
        R&D Progress ......................................................................................................................................................................... 20
    LEO 27989 .................................................................................................................................................................................. 21
        Product Description................................................................................................................................................................. 21
        Mechanism of Action ............................................................................................................................................................... 21
        R&D Progress ......................................................................................................................................................................... 21
    LEO 27989 + Calcipotriol............................................................................................................................................................. 22
        Product Description................................................................................................................................................................. 22
        Mechanism of Action ............................................................................................................................................................... 22
        R&D Progress ......................................................................................................................................................................... 22
    LEO 29102 .................................................................................................................................................................................. 24
        Product Description................................................................................................................................................................. 24
        Mechanism of Action ............................................................................................................................................................... 24
        R&D Progress ......................................................................................................................................................................... 24



LEO Pharma A/S – Product Pipeline Review – 2012                                                                                        GMDHC02166CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                      Page(2)
LEO Pharma A/S – Product Pipeline Review




    LEO 80185 Topical Suspension .................................................................................................................................................. 25
        Product Description................................................................................................................................................................. 25
        Mechanism of Action ............................................................................................................................................................... 25
        R&D Progress ......................................................................................................................................................................... 25
    LEO 90100 .................................................................................................................................................................................. 26
        Product Description................................................................................................................................................................. 26
        Mechanism of Action ............................................................................................................................................................... 26
        R&D Progress ......................................................................................................................................................................... 26
    LEO 90105 .................................................................................................................................................................................. 27
        Product Description................................................................................................................................................................. 27
        Mechanism of Action ............................................................................................................................................................... 27
        R&D Progress ......................................................................................................................................................................... 27
    LEO 90110 .................................................................................................................................................................................. 29
        Product Description................................................................................................................................................................. 29
        Mechanism of Action ............................................................................................................................................................... 29
        R&D Progress ......................................................................................................................................................................... 29
    LP 0058 ....................................................................................................................................................................................... 30
        Product Description................................................................................................................................................................. 30
        Mechanism of Action ............................................................................................................................................................... 30
        R&D Progress ......................................................................................................................................................................... 30
    LP 0067 ....................................................................................................................................................................................... 31
        Product Description................................................................................................................................................................. 31
        Mechanism of Action ............................................................................................................................................................... 31
        R&D Progress ......................................................................................................................................................................... 31
    Picato .......................................................................................................................................................................................... 32
        Product Description................................................................................................................................................................. 32
        Mechanism of Action ............................................................................................................................................................... 32
        R&D Progress ......................................................................................................................................................................... 32
    VBY-891 ...................................................................................................................................................................................... 34
        Product Description................................................................................................................................................................. 34
        Mechanism of Action ............................................................................................................................................................... 34
        R&D Progress ......................................................................................................................................................................... 34
LEO Pharma A/S – Pipeline Analysis ............................................................................................................................................... 35
    LEO Pharma A/S – Pipeline Products by Therapeutic Class ....................................................................................................... 35
    LEO Pharma A/S – Pipeline Products By Target ......................................................................................................................... 36
    LEO Pharma A/S – Pipeline Products by Route of Administration .............................................................................................. 37
    LEO Pharma A/S – Pipeline Products By Mechanism of Action .................................................................................................. 38
LEO Pharma A/S – Recent Pipeline Updates.................................................................................................................................. 39
LEO Pharma A/S - Dormant Projects ............................................................................................................................................... 40
LEO Pharma A/S - Discontinued Pipeline Products ......................................................................................................................... 41
    Discontinued Pipeline Product Profiles ........................................................................................................................................ 41
        CB1089 ................................................................................................................................................................................... 41
        LEO 80190 .............................................................................................................................................................................. 41
        Picato ...................................................................................................................................................................................... 42


LEO Pharma A/S – Product Pipeline Review – 2012                                                                                          GMDHC02166CDB / Published MAY 2012
©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                        Page(3)
LEO Pharma A/S – Product Pipeline Review




        TD1414 ................................................................................................................................................................................... 42
LEO Pharma A/S – Company Statement ......................................................................................................................................... 43
LEO Pharma A/S – Locations And Subsidiaries ............................................................................................................................... 44
    Head Office.................................................................................................................................................................................. 44
    Other Locations & Subsidiaries ................................................................................................................................................... 44
LEO Pharma A/S, Recent Developments ......................................................................................................................................... 46
    LEO Pharma A/S- Press Release................................................................................................................................................ 46
        Mar 14, 2012: New England Journal Of Medicine Reviews Benefits Of Leo Pharma's Ingenol Mebutate In Treatment Of
        Actinic Keratosis ..................................................................................................................................................................... 46
        Jan 25, 2012: FDA Approves LEO Pharma's Picato Gel For Topical Treatment Of Actinic Keratosis .................................... 47
        Dec 21, 2009: LEO Pharma Announces Positive Phase III Study Results Of PEP005 For The Treatment Of Lesions On
        Head Treatment Areas ............................................................................................................................................................ 48
        Aug 19, 2009: Peplin Completes Enrolment In Its Final Phase III Clinical Trial For PEP005 Gel In AK.................................. 48
        Jul 23, 2009: Peplin Initiates Its Final Phase III Clinical Trial For PEP005 Gel In AK ............................................................. 49
        Jun 08, 2009: Peplin Announces The Initiation Of Phase 3 Clinical Trials For PEP005 Gel In AK On The Face And Scalp .. 50
        Jun 04, 2009: LEO Pharma to expand in Russian market ...................................................................................................... 51
        May 27, 2009: Peplin’s Successful Phase II AK Trial Results Published In JAAD .................................................................. 51
        May 17, 2009: Positive Results For Peplin’s First Phase III AK Trial ...................................................................................... 52
        May 06, 2009: ATryn Available for Patients with Hereditary Antithrombin Deficiency, a Rare Blood Clotting Disorder .......... 53
        May 06, 2009: GTC Biotherapeutics Reports Launch of Atryn in the U.S. by Lundbeck Inc. .................................................. 53
        Mar 30, 2009: GTC Biotherapeutics Reports Progress in Preparations to Launch Atryn in the U.s. ....................................... 54
        Mar 13, 2009: GTC Biotherapeutics Provides Update on Agreement with Leo Pharma A/S .................................................. 54
        Mar 09, 2009: GTC Biotherapeutics Reports Progress in Atryn Program in U.S ..................................
								
To top